<p>Cassava Sciences Inc. has appointed Dawn C. Bir to its Board of Directors. Bir brings extensive experience from leadership roles at companies including Reata Pharmaceuticals, Geron Corporation, and Soleno Therapeutics. The company is preparing to begin its first clinical study for simufilam in TSC-related epilepsy in the first half of 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9549844-en) on October 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

SAVA

<p>Cassava Sciences Inc. has appointed Dawn C. Bir to its Board of Directors. Bir has significant experience from leadership roles at Reata Pharmaceuticals, Geron Corporation, and Soleno Therapeutics. The company plans to initiate its first clinical study for simufilam in TSC-related epilepsy in the first half of 2026.</p>

Cassava Sciences Appoints Dawn C. Bir to Board of Directors